Non-Small Cell Lung Cancer in Past Smokers Clinical Trial

TITLE:
A Randomized, Phase 2b, Multicenter Study of Pralatrexate Versus Erlotinib in Stage IIIB/IV Non-small Cell Lung Cancer After Failure of at Least One Prior Platinum-based Treatment

PURPOSE:
To study the efficacy of pralatrexate compared to erlotinib in patients with non-small cell lung cancer who have failed at least one platinum-based treatment.

PHASE:
2b

INSTITUTIONAL REVIEW BOARD:
Copernicus

STATUS:
Closed

ELIGIBILITY:
Patients aged 18 years or older with histologically or cytologically confirmed stage IIIb/IV non-small cell lung carcinoma relapsed after 1 or 2 prior chemotherapy regimens and who have smoked >100 cigarettes in a lifetime.

DURATION:

Principal Investigator:
Michael B. Wax, MD

CONTACT:
Isabella Rodrigues, PhD
Clinical Research Coordinator
908-277-8630